Geodon ziprasidone: Phase III started

RaQualia said Meiji Seika began a double-blind, placebo-controlled, Japanese Phase III trial to evaluate 40, 60 and 80 mg oral ziprasidone twice daily for 6 weeks in about 400 patients. Pfizer markets...